Log in
NASDAQ:ATRC

AtriCure Stock Forecast, Price & News

$43.84
+0.21 (+0.48 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$43.44
Now: $43.84
$44.14
50-Day Range
$34.56
MA: $39.26
$43.63
52-Week Range
$23.17
Now: $43.84
$51.76
Volume184,538 shs
Average Volume455,980 shs
Market Capitalization$1.97 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.92
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Read More
AtriCure logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.54 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100
Employees730

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$230.81 million
Book Value$9.27 per share

Profitability

Net Income$-35,190,000.00

Miscellaneous

Market Cap$1.97 billion
Next Earnings Date2/16/2021 (Estimated)
OptionableOptionable
$43.84
+0.21 (+0.48 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AtriCure (NASDAQ:ATRC) Frequently Asked Questions

How has AtriCure's stock price been impacted by Coronavirus (COVID-19)?

AtriCure's stock was trading at $35.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ATRC stock has increased by 24.3% and is now trading at $43.84.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of AtriCure?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AtriCure
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than AtriCure?

Wall Street analysts have given AtriCure a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AtriCure wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AtriCure's next earnings date?

AtriCure is scheduled to release its next quarterly earnings announcement on Tuesday, February 16th 2021.
View our earnings forecast for AtriCure
.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) announced its quarterly earnings data on Tuesday, November, 10th. The medical device company reported ($0.11) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.34) by $0.23. The medical device company had revenue of $54.80 million for the quarter, compared to analysts' expectations of $49.37 million. AtriCure had a negative return on equity of 14.83% and a negative net margin of 21.74%. The firm's revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.33) EPS.
View AtriCure's earnings history
.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its fourth quarter 2020 After-Hours earnings guidance on Thursday, November, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $56-60 million, compared to the consensus revenue estimate of $62.05 million.

What price target have analysts set for ATRC?

7 analysts have issued 12 month price objectives for AtriCure's shares. Their forecasts range from $45.00 to $60.00. On average, they anticipate AtriCure's stock price to reach $53.29 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price.
View analysts' price targets for AtriCure
.

Who are some of AtriCure's key competitors?

What other stocks do shareholders of AtriCure own?

Who are AtriCure's key executives?

AtriCure's management team includes the following people:
  • Mr. Michael H. Carrel, CEO, Pres & Director (Age 49, Pay $1.83M)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 54, Pay $967.43k)
  • Mr. Salvatore Privitera J.D., Chief Technical Officer (Age 53, Pay $639.99k)
  • Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 42, Pay $632.13k)
  • Mr. M. Andrew Wade CPA, CPA, Advisor (Age 45, Pay $727.06k)
  • Ms. Angela L. Wirick, Chief Financial Officer
  • Dr. Vinayak Doraiswamy, Sr. VP of Clinical, Regulatory, Scientific & Medical Affairs
  • Mr. Karl Dahlquist, Chief Legal Officer
  • Ms. Tonya Austin, Sr. VP of HR
  • Valerie Storch-Willhaus, Sr. Director of Corp. Marketing & Communications

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.94%), Champlain Investment Partners LLC (4.60%), State Street Corp (2.32%), Wasatch Advisors Inc. (2.05%), GW&K Investment Management LLC (1.93%) and Neuberger Berman Group LLC (1.63%). Company insiders that own AtriCure stock include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel, Regina E Groves and Scott William Drake.
View institutional ownership trends for AtriCure
.

Which institutional investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Arrowstreet Capital Limited Partnership, Voloridge Investment Management LLC, Sei Investments Co., Emerald Advisers LLC, Acuitas Investments LLC, Acuitas Investments LLC, and Rothschild & Co. Asset Management US Inc.. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel, and Regina E Groves.
View insider buying and selling activity for AtriCure
.

Which institutional investors are buying AtriCure stock?

ATRC stock was bought by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, BlackRock Inc., Oak Ridge Investments LLC, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Wasatch Advisors Inc., Polar Capital LLP, Polar Capital LLP, and State Street Corp. Company insiders that have bought AtriCure stock in the last two years include Regina E Groves, and Scott William Drake.
View insider buying and selling activity for AtriCure
.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $43.84.

How big of a company is AtriCure?

AtriCure has a market capitalization of $1.97 billion and generates $230.81 million in revenue each year. The medical device company earns $-35,190,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. AtriCure employs 730 workers across the globe.

What is AtriCure's official website?

The official website for AtriCure is www.atricure.com.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.